Get the Stockscreener App
144.85
1.29%
1.725
Insmed Inc stock is traded at $144.85, with a volume of 190.16K.
It is up +1.29% in the last 24 hours and down -2.41% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$143.13
Open:
$142.84
24h Volume:
190.16K
Relative Volume:
0.07
Market Cap:
$31.25B
Revenue:
$606.42M
Net Income/Loss:
$-1.28B
P/E Ratio:
-22.62
EPS:
-6.403
Net Cash Flow:
$-997.58M
1W Performance:
-1.38%
1M Performance:
-2.41%
6M Performance:
-0.65%
1Y Performance:
+98.41%
1-Day Range:
$142.84
$145.18
1-Week Range:
$138.82
$150.27
52-Week Range:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
144.98 | 30.85B | 606.42M | -1.28B | -997.58M | -6.403 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.76 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.63 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
741.08 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.08 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
307.47 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
INSM stock jumps on 2025 preliminary sales, 2026 goals announced - MSN
Victory Capital Management Inc. Boosts Position in Insmed, Inc. $INSM - MarketBeat
Is Insmed Incorporated stock a safe investment in uncertain marketsInsider Selling & Free Technical Pattern Based Buy Signals - Naître et grandir
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA - Finviz
Institution Moves: What are the future prospects of Insmed IncorporatedBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed Breaks Below 200-Day Moving AverageNotable for INSM - Nasdaq
Insmed Grants Inducement Awards to 85 New Employees - Intellectia AI
GW&K Investment Management LLC Sells 672,513 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed hands 85 new employees stock units and long-term options - Stock Titan
Picton Mahoney Asset Management Sells 34,001 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmonary Arterial Hypertension Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therap - Barchart.com
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? - Yahoo Finance
Insmed, Inc. $INSM Shares Sold by Rafferty Asset Management LLC - MarketBeat
10 Stocks That Could Skyrocket in 2026 - Insider Monkey
Insmed’s BRINSUPRI Outperformance Puts Commercial Execution And Valuation In Focus - simplywall.st
Insmed Incorporated (INSM): Investor Outlook Reveals A Promising 42% Upside - DirectorsTalk Interviews
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations - Yahoo Finance
Insmed at TD Cowen Conference: Strategic Growth and Market Expansion - Investing.com South Africa
INSM: Strong Q4 launch, expanding access, and promising pipeline set stage for significant growth - TradingView
HC Wainwright Has Negative Outlook of Insmed FY2026 Earnings - MarketBeat
William Blair Investment Management LLC Has $223.94 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz
10 Unstoppable Stocks to Buy and Hold for the Next 3 Years - Insider Monkey
Insmed (INSM) director gifts shares and details family holdings - Stock Titan
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Artisan Partners Limited Partnership Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Why Insmed (INSM) Is Down 6.8% After Wider 2025 Losses But Rapid Brinsupri Launch Traction - simplywall.st
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
INSMED Chief Legal Officer Sells Shares Worth Over $3.8 Million - TradingView
Insmed (INSM) CLO exercises options and sells 24,774 shares - Stock Titan
Director David R. Brennan gifts 6,000 INSM (NASDAQ: INSM) shares in Form 4 - Stock Titan
United unveils newly partnered soft mist inhaler; Mannkind sinks - bioworld.com
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Brown Advisory Small-Cap Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
INSM (NASDAQ: INSM) reports Michael Smith sales and issuer plan issuances - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
H.C. Wainwright Remains a Buy on Insmed (INSM) - The Globe and Mail
INSM Stock Rating: Mizuho Lowers Price Target Amid Consistent Ou - GuruFocus
Mizuho Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE - Yahoo Finance
HC Wainwright Comments on Insmed's Q1 Earnings (NASDAQ:INSM) - MarketBeat
Insmed chair and CEO Lewis sells $1.6m in stock By Investing.com - Investing.com Nigeria
Insmed chair and CEO Lewis sells $1.6m in stock - Investing.com
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target SetWhat's Changed - Yahoo Finance
H.C. Wainwright reiterates Buy on Insmed stock, $230 target By Investing.com - Investing.com UK
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 05 '26 |
Option Exercise |
24.94 |
10,699 |
266,840 |
311,884 |
| Lewis William | Chair and CEO |
Mar 05 '26 |
Sale |
146.03 |
10,699 |
1,562,328 |
301,185 |
| Smith Michael Alexander | Chief Legal Officer |
Feb 24 '26 |
Option Exercise |
17.07 |
20,248 |
345,633 |
76,645 |
| Smith Michael Alexander | Chief Legal Officer |
Feb 24 '26 |
Sale |
155.77 |
24,774 |
3,859,157 |
51,871 |
1.72%
3.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):